Theurillat Group
Theurillat Group

We aim to explore the role of SPOP and CHD1 mutations to develop new therapeutic avenues for prostate cancer.

Alimonti group
Alimonti group

Our research is focused on the characterization of a novel type of cellular senescence response for cancer therapy

Catapano group
Catapano group

We investigate strategies aimed at blocking selectively transcription of genes that might be implicated in pathogenesis of cancer

Bertoni group
Bertoni group

We apply genomics techniques followed by functional studies to elucidate the lesions underlying non-Hodgkin’s lymphomas

Fighting cancer through research. You can support us by making a donation, however large or small.

Support us

Portrait

The Institute of Oncology Research (IOR), established in 2003 in Bellinzona, Switzerland, hosts researchers from all over the world performing basic and translational research in oncology with special focus on:

  • cancer biology
  • genomics
  • molecular oncology
  • experimental therapeutics.

At the Institute of Oncology Research we believe that science is constantly evolving to improve our understanding of human cancer.

The efforts of our researchers and the resources of the institute are directed towards this challenge, with a commitment to discovering practical and far-reaching solutions to a disease that still impacts on the everyday life of people around the world.

news

Pfizer Prize 2020, awards for IOR and IRB researchers in oncology and neurology
7 Feb

Pfizer Prize 2020, awards for IOR and IRB researchers in oncology and neurology

The awards for the 29th Pfizer Prize for Research were given on Thursday, February 6, in Zuric...
A new publication by Prof. Francesco Bertoni LAB
4 Feb

A new publication by Prof. Francesco Bertoni LAB

Antibody-drug conjugates (ADCs) are an effective therapeutic modality to deliver potent cytotoxic mo...

Research

Jobs

Publications